KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes.

Taylor M Triolo, Laura M Jacobsen, David Cuthbertson, Emily K Sims, Heba M Ismail, Maria J Redondo, Markus Lundgren, Linda A DiMeglio, Peter A Gottlieb, Mark A Atkinson, Jeffrey P Krischer, Desmond A Schatz, Jay M Sosenko

Pediatr Diabetes 2024 8343868

PMID40302969
PMCIDPMC12016772
DOI10.1155/2024/8343868
发表日期2025-04-30
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Background: The TrialNet Oral Insulin (OI) prevention trial showed no overall treatment effect, using the diagnosis of type 1 diabetes as an endpoint. A significant delay in onset was only found in a high-risk stratum (termed secondary stratum 1) of participants with low first-phase insulin release (FPIR). Methods: Since trials with an endpoint of type 1 diabetes take years to complete, in this post hoc analysis, we assessed whether a novel combination of glucose and C-peptide markers could identify a therapeutic benefit after 1 year of follow-up (trial participants followed for a median 2.7 years). Results: Participants were relatives with multiple islet autoantibodies and low FPIR (n = 40). Glucose rose, and C-peptide declined in the placebo group, whereas glucose rose minimally, and C-peptide increased in the OI group. When glucose and C-peptide were plotted on two-dimensional grids using 30-120-min oral glucose tolerance test (OGTT) time points, changes in ratios of their central points (centroid ratio) differed between groups (p=0.037 adjusted for age, BMI, and baseline C-peptide and glucose). Conclusions: These findings support a favorable early effect of OI on combined glucose and C-peptide endpoints in high-risk individuals, indicating metabolic benefit. With further study, these measures may allow for shorter trials compared to the standard endpoint of type 1 diabetes diagnosis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。